Dr. Suhas Singla is a highly experienced nuclear medicine specialist with an MD in nuclear medicine from the All India Institute of Medical Sciences, Delhi. With expertise in both diagnostic and therapeutic applications, he is proficient in PET-CT, SPECT-CT, and targeted molecular therapies. He pioneered the initiation of 177Lu-DOTATATE therapy in India under the mentorship of Prof. C.S. Bal at AIIMS, Delhi, and later introduced both 177Lu-PSMA and 177Lu-DOTATATE therapies in Noida. With over 14 international publications, Dr. Singla combines innovation with evidence-based practice to deliver precision care for complex oncological conditions.
Diagnostic oncoimaging with FDG, PSMA, DOPA, Choline, NOTA PET-CT
All SPECT-CT procedures
177Lu-DOTATATE therapy for unresectable neuroendocrine tumours
177Lu-PSMA therapy for advanced castrate-resistant prostate cancer
MBBS | MD - Nuclear Medicine
Derived from verified patient bills.
Dr. Suhas Singla is a highly experienced nuclear medicine specialist with an MD in nuclear medicine from the All India Institute of Medical Sciences, Delhi. With expertise in both diagnostic and therapeutic applications, he is proficient in PET-CT, SPECT-CT, and targeted molecular therapies. He pioneered the initiation of 177Lu-DOTATATE therapy in India under the mentorship of Prof. C.S. Bal at AIIMS, Delhi, and later introduced both 177Lu-PSMA and 177Lu-DOTATATE therapies in Noida. With over 14 international publications, Dr. Singla combines innovation with evidence-based practice to deliver precision care for complex oncological conditions.
Initiated 177Lu-DOTATATE therapy for the first time in India (2007), Initiated 177Lu-PSMA and 177Lu-DOTATATE therapy in Noida
